MedTrace Logo

Addition of Lactobacillus to Metronidazole in Treatment of CDAD

NCT00304863 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2017-05-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether dietary supplementation with Lactobacillus GG will reduce the rate of failure or relapse following treatment of CDAD with metronidazole.

Conditions

  • Enterocolitis
  • Pseudomembranous Colitis
  • Antibiotic-associated Colitis

Interventions

DRUG

Lactobacillus GG

This arm will receive the additional probiotic of lactobacillus GG

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • Michael E. DeBakey VA Medical Center

    lead FED

Principal Investigators

  • Daniel M Musher, M.D. · Baylor College of Medicine, Houston VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-01
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304863 on ClinicalTrials.gov